Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Rate of functional decline in Huntington's disease. Huntington Study Group.

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I.

Neurology. 2000 Jan 25;54(2):452-8. Erratum in: Neurology 2000 Apr 25;54(8):1712.

PMID:
10668713
2.

The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.

Youssov K, Dolbeau G, Maison P, Boissé MF, Cleret de Langavant L, Roos RA, Bachoud-Lévi AC.

Mov Disord. 2013 Dec;28(14):1995-2001. doi: 10.1002/mds.25678. Epub 2013 Oct 9.

PMID:
24123464
3.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators.

Lancet Neurol. 2012 Jan;11(1):42-53. doi: 10.1016/S1474-4422(11)70263-0. Epub 2011 Dec 2.

PMID:
22137354
4.

Unified Huntington's disease rating scale for advanced patients: validation and follow-up study.

Youssov K, Dolbeau G, Maison P, Boissé MF, Cleret de Langavant L, Roos RA, Bachoud-Lévi AC.

Mov Disord. 2013 Oct;28(12):1717-23. doi: 10.1002/mds.25654.

5.

Unified Huntington's disease rating scale: a follow up.

Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA.

Mov Disord. 1998 Nov;13(6):915-9.

PMID:
9827615
6.

Functional decline in Huntington's disease.

Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I.

Mov Disord. 1995 Mar;10(2):211-4.

PMID:
7753064
7.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators.

Lancet Neurol. 2013 Jul;12(7):637-49. doi: 10.1016/S1474-4422(13)70088-7. Epub 2013 May 9.

PMID:
23664844
8.

Electrophysiological deterioration over time in patients with Huntington's disease.

Lefaucheur JP, Ménard-Lefaucheur I, Maison P, Baudic S, Cesaro P, Peschanski M, Bachoud-Lévi AC.

Mov Disord. 2006 Sep;21(9):1350-4.

PMID:
16721731
9.

Rate of change in early Huntington's disease: a clinicometric analysis.

Meyer C, Landwehrmeyer B, Schwenke C, Doble A, Orth M, Ludolph AC; EHDI Study Group.

Mov Disord. 2012 Jan;27(1):118-24. doi: 10.1002/mds.23847. Epub 2011 Nov 17.

PMID:
22095693
10.

Assessment of adaptive functioning in Huntington's disease.

Bylsma FW, Rothlind J, Hall MR, Folstein SE, Brandt J.

Mov Disord. 1993 Apr;8(2):183-90.

PMID:
8474487
11.

Severity of cognitive impairment in juvenile and late-onset Huntington disease.

Gómez-Tortosa E, del Barrio A, García Ruiz PJ, Pernaute RS, Benítez J, Barroso A, Jiménez FJ, García Yébenes J.

Arch Neurol. 1998 Jun;55(6):835-43.

PMID:
9626775
12.

Correlates of early disability in Huntington's disease.

Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S.

Ann Neurol. 1986 Dec;20(6):727-31.

PMID:
2949692
13.

Weight loss in early stage of Huntington's disease.

Djoussé L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH.

Neurology. 2002 Nov 12;59(9):1325-30.

PMID:
12427878
14.

The influence of gender on phenotype and disease progression in patients with Huntington's disease.

Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, Marcinkowski J, Squitieri F, Bentivoglio AR, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2013 Feb;19(2):192-7. doi: 10.1016/j.parkreldis.2012.09.012. Epub 2012 Oct 25.

PMID:
23102616
15.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

PMID:
28642124
16.
17.

A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease.

Collins LM, Lazic SE, Barker RA.

BMC Neurol. 2014 Feb 24;14:35. doi: 10.1186/1471-2377-14-35.

18.

Complex movement behaviour and progression of Huntington's disease.

Andrich J, Saft C, Ostholt N, Müller T.

Neurosci Lett. 2007 Apr 18;416(3):272-4. Epub 2007 Feb 11.

PMID:
17321683
19.

The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.

Salem L, Saleh N, Youssov K, Olivier A, Charles P, Scherer C, Verny C, Bachoud-Lévi AC, Maison P.

Fundam Clin Pharmacol. 2014 Dec;28(6):700-10. doi: 10.1111/fcp.12077. Epub 2014 May 9. Review.

PMID:
24702447
20.

Relationship between Nutritional Status and the Severity of Huntington’s Disease. A Spanish Multicenter Dietary Intake Study.

Cubo E, Rivadeneyra J, Armesto D, Mariscal N, Martinez A, Camara RJ; Spanish members of the European Huntington Disease Network.

J Huntingtons Dis. 2015;4(1):78-85.

PMID:
26333259

Supplemental Content

Support Center